ResMed (RMD) Q2 Earnings and Revenues Beat Estimates

分组1 - ResMed reported quarterly earnings of $2.81 per share, exceeding the Zacks Consensus Estimate of $2.69 per share, and showing an increase from $2.43 per share a year ago, resulting in an earnings surprise of +4.59% [1] - The company achieved revenues of $1.42 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.30%, and up from $1.28 billion year-over-year [2] - ResMed has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has gained approximately 7% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at $2.75 for the coming quarter and $10.86 for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 37% of over 250 Zacks industries, which may impact stock performance [8]